Phase 4 N=54 Reversing Corticosteroid Induced Memory Impairment
Memory Impairment
Primary: The Rey Auditory Verbal Learning Test (RAVLT) — 45.741; 43.286 T Score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=28 Clinical Trial of Lamotrigine to Reverse Cognitive Impairment in Chronic Corticosteroid-Treated Patients
Memory Impairment Due to Corticosteroid Use · Hypomania Due to Corticosteroid Use · Hippocampal Atrophy Due to Corticosteroid
Primary: Rey Auditory Verbal Learning Test (RAVLT) — 46.1; 40.1 T-scores
Phase 4 N=30 Acetaminophen (Tylenol) for Mood and Memory Changes Associated With Corticosteroid Therapy
Asthma · Rheumatic Disease
Primary: Rey Auditory Verbal Learning Test (RAVLT) — 44.8; 44.1 words
Phase 4 N=66 Exploring the Effects of Corticosteroids on the Human Hippocampus
Hydrocortisone · Depression · Healthy Volunteers
Primary: Hippocampal Subfield Activation (Left Hemisphere) — -0.35; 0.03; -0.08; -0.07 Z-Score
Phase 2 N=24 Vilazodone for Corticosteroid-Induced Memory Impairment
Memory Impairment
Primary: Change From Baseline RAVLT (Rey Auditory Verbal Learning Test) Total T-Score at Day 19 — -3; 0 T-score
Phase 4 N=46 Attenuation of Corticosteroid Induced Hippocampal Changes
Organic Memory Impairment
Primary: Hopkins Verbal Learning Test-Revised (HVLT-R) Total Score — 39.40; 36.93; 37.67; 38.37 units on a scale
Phase 3 N=17 Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes
Healthy
Primary: Difference in RAVLT Total T-Score Between Treatments — 57.76; 56.11; 53.08; 42.76 T-score — p=<0.01
Phase 2 N=15 Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders
Anxiety Disorders
Primary: Drug Acceptability, as Measured by Number of Participants With Dose-limiting Side Effects — 1 Participants
N/A N=30 Adjunctive Pregnenolone in Veterans With Mild TBI
Traumatic Brain Injury
Primary: Brief Assessment of Cognition in Affective Disorders (BAC-A) — 0.61; 0.80 units on a scale
Phase 4 N=85 Inpatient Diabetes on Corticosteroids
Diabetes Mellitus
Primary: Mean POC Glucose Level Between Groups — 225; 266 mg/dl
Phase 4 N=12 Short Course Glucocorticoid Treatment for PTSD
Post-traumatic Stress Disorder
Primary: Change in Clinician-Administered PTSD Scale (CAPS) — 96.0; 90.7; 66.3; 86.2 score on a scale
Phase 4 N=21 Phenytoin for Memory Impairment Secondary to Megestrol
Cognitive Impairment
Primary: Rey Auditory Verbal Learning Test (RAVLT) — 51.89; 45.90; 48.37 T-scores — p=0.003
Phase 4 N=60 Characterizing and Predicting Drug Effects on Cognition
Cognitive Deficits
Primary: Change From Baseline in COWA Unique Word Count — -0.407725385; -0.425898667; -0.412534118; -0.108298333 Word Count
Phase 4 N=30 Steroids in Bilateral Total Knee Replacement
Postoperative Inflammatory Response
Primary: Decrease in IL6 Level — 359.4; 381.6 pg/ml
Phase 3 N=53 Prevention of Metabolic Complications of Glucocorticoid Excess
Iatrogenic Cushing Disease
Primary: CT Abdomen — 0.08; -0.03 ratio
N/A N=7 Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate
Adrenal Insufficiency
Primary: Number of Participants With Adrenal Insufficiency — 7 participants
Phase 4 N=60 Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT)
Adrenal Insufficiency
Primary: Change in Cognition After 10 Weeks of Treatment With a Low Dose of Hydrocortisone Compared to 10 Weeks of Treatment With a High Dose of Hydrocortisone. — -0.41; -0.42…
Phase 4 N=72 Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia
Hyperglycemia
Primary: Mean Blood Glucose of All Readings — 157.2; 181.8 mg/dL
N/A N=43 Peri-Operative Steroid Management in Patients
Pituitary Adenoma · Pituitary Diseases
Primary: Number of Participants With Adrenal Insufficiency — 2; 1 Participants
N/A N=76 Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)
Brain Injury
Primary: Neuropsychological Assessment, CVLT-II — 51.3; 51.8; 51.9; 57.2 units on a scale — p=<0.04
Phase 2 N=53 Neuroactive Steroids and Traumatic Brain Injury (TBI) in OEF/OIF Veterans
Brain Injuries, Traumatic
Primary: CAPS (Cluster D Symptoms) - PRIMARY BEHAVIORAL OUTCOME MEASURE — 13.88; 12.89; 11.23; 10.89 Score
N/A N=62 Extinction of Fear Memories With Glucocorticoids in Veterans With PTSD
Posttraumatic Stress Disorder
Primary: PTSD Checklist (PCL). A Self-report, Face Valid Measure of PTSD Symptoms Over a 1 Week Time Period — 55.76; 54.83; 50.14; 51.57 units on a scale
Phase 3 N=61 Effects of Dalfampridine on Cognition in Multiple Sclerosis
Multiple Sclerosis
Primary: Symbol Digit Modalities Test — 41.18; 35.06; 45.05; 38.63 score on a scale
Phase 2 N=19 Intranasal Insulin and Post-stroke Cognition: A Pilot Study
Stroke
Primary: Composite of Memory t Scores — 39.5; 39.7 score on a scale
N/A N=173 Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
Severe Acute Respiratory Syndrome (SARS) Pneumonia · Coronavirus Infections · ARDS, Human
Primary: Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28 — 19; 40 Participants
Phase 4 N=200 Effect of Low-Dose Dexamethasone on the Incidence of Hyperglycemia Following Surgery
Postoperative Complications
Primary: Serum Blood Glucose Concentrations — 101; 137; 140; 141 mg/dl
Phase 4 N=37 The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
Hyperglycemia · Diabetes Mellitus
Primary: Average Daily Glucose Levels on Days 1-5 After the Initiation of the Treatment Protocol. — 181.8; 173.7; 160.5; 148.4 mg/dL — p=0.35
Phase 4 N=105 Steroid Withdrawal and Donor-specific Anti-HLA Antibodies in Renal Transplant Patients
Other Complication of Kidney Transplant · Renal Transplant Rejection
Primary: Cases of Kidney Transplant Patients With DSA — 0; 0 Participants
Phase 3 N=584 Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e)
Community Acquired Respiratory Disease Syndrome
Primary: 60-day Mortality — 50; 47; 227; 239 Participants — p=0.635
Phase 2 N=116 Effect of Steroids on Post-tonsillectomy Morbidities
Postoperative Pain · Postoperative Nausea and Vomiting
Primary: Maximum Severity of Post-operative Pain — 37; 26; 13; 21 participants — p=0.033